Don Hayden brings experience and insight to the REGENXBIO Board. Mr. Hayden had a highly successful 25-year career with Bristol-Myers Squibb Company and continues to hold key roles at a number of entrepreneurial pharmaceutical and biotech companies.
At Bristol-Myers Squibb, he served as president of Global Pharmaceuticals; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group; president of Oncology and Immunology; and senior vice president for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, he has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals, Nora Therapeutics, and Dimension Therapeutics.
Mr. Hayden received an M.B.A. from Indiana University and his undergraduate degree from Harvard University.